Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

Cancer(2020)10.1002/cncr.33072Source: DataRank Database

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy is a research paper published in Cancer (2020). On theSindex it has a DataRank of 0. It has been cited 8 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access8 citations

Download PDF

Cite:

Linked data & code

nct

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (4 grants)OA: hybridTopics (27)IDs (PubMed, PMC)Annotations (1)SDGs (1)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (8)

Timothy Bell ORCID,Young‐Min Kwon ORCID,Joseph C. Cappelleri ORCID,Courtney Johnson ORCID,Helen Bhattacharyya

Live enrichment

PubMed:32697335 PMC:PMC7540307

National Institutes of Health

Grant: P30 CA016672

National Institutes of Health

Grant: 3P30CA016672-41S4

Cancer Center Support (CORE) Grant

University of Texas MD Anderson Cancer Center

Pfizer

hybridLicense: cc-by-nc

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdfdirect/10.1002/cncr.33072

publisherhttps://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1002%2Fcncr.33072

publisherhttps://onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33072

publisherhttps://onlinelibrary.wiley.com/doi/full-xml/10.1002/cncr.33072

publisherhttps://acsjournals.onlinelibrary.wiley.com/doi/pdf/10.1002/cncr.33072

Fields of Study

03 medical and health sciences0302 clinical medicine

MeSH Terms

HumansPhenylurea CompoundsBenzimidazolesCytarabineAntineoplastic Combined Chemotherapy ProtocolsSurvival AnalysisFemaleMaleLeukemia, Myeloid, Acute

Keywords

Acute myeloid leukemiaQuality of lifeLow-dose CytarabineQuality-adjusted SurvivalQuality-adjusted Time Without Symptoms Of Disease Progression Or Toxicity (Q-twist)GlasdegibMaleLeukemia, Myeloid, AcutePhenylurea CompoundsAntineoplastic Combined Chemotherapy ProtocolsCytarabineHumansBenzimidazolesFemaleOriginal ArticlesSurvival Analysis

Sustainable Development Goals

SDG 3: 3. Good health

A quality‐adjusted survival time without symptoms or toxicities analysis of glasdegib plus low‐dose cytarabine versus low‐dose cytarabine as initial therapy for acute myeloid leukemia in patients who are not considered candidates for intensive chemotherapy

FAIR Checklist

Authors (8)

Funding (4 grants)

Open Access

Topics

Annotations (Europe PMC)